Thursday, October 15, 2026

HNI Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

HNI Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Crown Castle International Corp.

6.2% sales growth and 10.38% return on equity

Crown Castle owns, operates and leases more than 40,000 cell towers and approximately 80,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market.

Crown Castle International Corp.'s sales growth this year is expected to be 6.3% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 4.5%, now sitting on 5.9B for the twelve trailing months.

Crown Castle International Corp.'s sales growth for the next quarter is 6.2%. The company's growth estimates for the present quarter and the next is 43.9% and 65.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.38%.

Volatility

Crown Castle International Corp.'s last day, last week, and last month's current volatility was 0.72%, 0.55%, and 0.94%, respectively.

Crown Castle International Corp.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.35% (day), 1.77% (last week), and 1.76% (last month), respectively.

Crown Castle International Corp.'s Stock Yearly Top and Bottom Value

Crown Castle International Corp.'s stock is valued at $184.21 at 05:22 EST, under its 52-week high of $185.97 and way above its 52-week low of $146.15.

Crown Castle International Corp.'s Moving Average

Crown Castle International Corp.'s value is way higher than its 50-day moving average of $161.76 and way above its 200-day moving average of $161.29.

3. Corporate Office Properties Trust

8.2% sales growth and 5.93% return on equity

COPT is a REIT that owns, manages, leases, develops and selectively acquires office and data center properties.

Corporate Office Properties Trust's sales growth this year is anticipated to be 7% and a negative 0.2% for next year.

Year-on-year quarterly revenue growth grew by 4%, now sitting on 611.19M for the twelve trailing months.

Corporate Office Properties Trust's sales growth for the next quarter is 8.2%. The company's growth estimates for the ongoing quarter and the next is 4.8% and 4.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.93%.

Volatility

Corporate Office Properties Trust's last day, last week, and last month's current volatility was 0.61%, 0.80%, and 0.95%, respectively.

Corporate Office Properties Trust's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.30% (day), 1.54% (last week), and 1.94% (last month), respectively.

Corporate Office Properties Trust's Stock Yearly Top and Bottom Value

Corporate Office Properties Trust's stock is valued at $27.95 at 05:22 EST, under its 52-week high of $28.50 and way higher than its 52-week low of $20.93.

Corporate Office Properties Trust's Moving Average

Corporate Office Properties Trust's value is higher than its 50-day moving average of $27.20 and above its 200-day moving average of $26.02.

4. HNI Corporation

11.6% sales growth and 7.13% return on equity

HNI Corporation manufacturHON Industries Inc.es and sells office furniture and hearth products in the United States, Canada, China, Hong Kong, India, Mexico, Dubai, Taiwan, and Singapore.

HNI Corporation's sales growth this year is anticipated to be 5.1% and 5.4% for next year.

Year-on-year quarterly revenue growth declined by 8.8%, now sitting on 1.96B for the twelve trailing months.

HNI Corporation's sales growth for the next quarter is 11.6%. The company's growth estimates for the ongoing quarter and the next is a negative 57.1% and 10%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.13%.

Volatility

HNI Corporation's last day, last week, and last month's current volatility was 1.20%, 1.04%, and 1.11%, respectively.

HNI Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.33% (day), 3.17% (last week), and 2.89% (last month), respectively.

HNI Corporation's Stock Yearly Top and Bottom Value

HNI Corporation's stock is valued at $41.67 at 05:22 EST, below its 52-week high of $43.85 and way higher than its 52-week low of $19.09.

HNI Corporation's Moving Average

HNI Corporation's value is higher than its 50-day moving average of $40.23 and way higher than its 200-day moving average of $36.77.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com